



February 13, 2026

To Whom It May Concern,

Company name: Hoky Medical Co., Ltd.
Representative: Hideki Kawakubo, President and CEO
Securities code: 3593 (Tokyo Stock Exchange, Prime Market)
Inquiries: Taisuke Fujita, Executive Vice President and CFO
(Tel: +81-3-6229-1300)

(Amendment) Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for the Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593) by TCG2509 Co., Ltd.”

TCG2509 Co., Ltd. has submitted an amendment to the Tender Offer Registration Statement to the Kanto Local Finance Bureau Chief concerning the tender offer for the common shares of Hoky Medical Co., Ltd., originally filed on December 18, 2025 (including the information amended by the amendment statements submitted on December 25, 2025, January 6, 2026 and February 5, 2026). This includes the Public Notice of Commencement of Tender Offer dated December 18, 2025 (also including the information amended by the amendment statements submitted on December 25, 2025, January 6, 2026 and February 5, 2026, and the information amended by the public notice of changes to the tender offer terms dated February 5, 2026). This amendment arises from the reduction of the waiting period stipulated in the main clause of Article 27, Paragraph 2 of the Foreign Exchange and Foreign Trade Act (Act No. 228 of 1949, as amended), pursuant to the proviso of said paragraph, enabling acquisition of common stock of Hoky Medical Co., Ltd. Additionally, TCG2509 Co., Ltd. extended the Tender Offer Period to 45 business days, ending on March 2, 2026, which is 10 business days after the submission date of the amendment statement on February 13, 2026. As a result, certain items in the Tender Offer Registration Statement and the Public Notice of Commencement of Tender Offer require amendments. Therefore, the Offeror has submitted an amendment to the Tender Offer Registration Statement pursuant to Article 27-8, Paragraph 2 of the Financial Instruments and Exchange Act. Consequently, the information contained in the “Notice Regarding Commencement of Tender Offer for the Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” dated December 17, 2025 (including amendments made by the “Amendments to the ‘Notice Regarding Commencement of Tender Offer for the Common Stocks of Hoky Medical Co., Ltd. (Securities Code: 3593)’ and the Public Notice of Commencement of Tender Offer” published on December 25, 2025, January 6, 2026 and February 5, 2026) has been amended as set forth in the attached document.

This disclosure is being made pursuant to Article 30, Paragraph 1, Item 4 of the Order for Enforcement of the Financial Instruments and Exchange Act, based on a request from TCG2509 Co., Ltd. (the Offeror) to Hoky Medical Co., Ltd. (the company subject to the tender offer).

(Attachment)

“Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” and the Public Notice Regarding Commencement of Tender Offer” dated February 13, 2026

February 13, 2026

To Whom It May Concern,

Company Name: TCG2509 Co., Ltd.
Representative: Representative Director
Genta Saito

(Amendment) Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” and the Public Notice Regarding Commencement of Tender Offer

TCG2509 Co., Ltd. (the “Offeror”) decided at a meeting of its Board of Directors held on December 17, 2025, to acquire common stock (the “Target Shares”) of Hoky Medical Co., Ltd. (Tokyo Stock Exchange Prime Market, Securities Code: 3593, the “Target”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended) (the “Act”), and commenced the Tender Offer on December 18, 2025. The Offeror has submitted an amendment to the Tender Offer Registration Statement to the Kanto Local Finance Bureau Chief concerning the Tender Offer, originally filed on December 18, 2025 (including the information amended by the amendment statements submitted on December 25, 2025, January 6, 2026 and February 5, 2026; the same applies hereinafter). This includes the Public Notice of Commencement of Tender Offer dated December 18, 2025 (also including the information amended by the amendment statements submitted on December 25, 2025, January 6, 2026 and February 5, 2026, and the information amended by the public notice of changes to the tender offer terms dated February 5, 2026; the same applies hereinafter). This amendment arises from the reduction of the waiting period stipulated in the main clause of Article 27, Paragraph 2 of the Act, pursuant to the proviso of said paragraph, enabling acquisition of common stock of the Target. Additionally, the Offeror extended the Tender Offer Period to 45 business days, ending on March 2, 2026, which is 10 business days after the submission date of the amendment statement on February 13, 2026. As a result, certain items in the Tender Offer Registration Statement and the Public Notice of Commencement of Tender Offer require amendments. Therefore, the Offeror has submitted an amendment to the Tender Offer Registration Statement pursuant to Article 27-8, Paragraph 2 of the Financial Instruments and Exchange Act.

Accordingly, the Offeror hereby announces that it has amended the “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” dated December 17, 2025 (including the information amended by the “(Amendment) Notice Regarding Amendment of ‘Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)’ and the Public Notice Regarding Commencement of Tender Offer” announced on December 25, 2025, January 6, 2026 and February 5, 2026), and the

Public Notice Regarding Commencement of Tender Offer dated December 18, 2025, as described below.

The amended portions are underlined.

[I] Amendment of the “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” dated December 17, 2025

I. DETAILS OF THE TENDER OFFER

C. Tender Offer Period

(Before amendment)

From December 18, 2025 (Thursday) to February 20, 2026 (Friday) (40 business days)

(After amendment)

From December 18, 2025 (Thursday) to March 2, 2026 (Monday) (45 business days)

F. Settlement Start Date

(Before amendment)

March 2, 2026 (Monday)

(After amendment)

March 9, 2026 (Monday)

II. OUTLINE OF THE TENDER OFFER

(Before amendment)

<Text omitted>

On February 4, 2026, following the conclusion of discussions between the Offeror and the relevant authorities regarding the notification required under Article 27, Paragraph 1 of the Foreign Exchange and Foreign Trade Act, the Offeror, upon receiving instructions from the Ministry of Economy, Trade and Industry and the Ministry of Health, Labor and Welfare, resubmitted the notification to the Minister of Finance and the Minister in charge of the relevant business sector via the Bank of Japan on February 4, 2026, which was accepted on the same date. Consequently, the Offeror submitted an amendment to the Tender Offer Registration Statement and extended the Tender Offer Period to February 20, 2026, which is the date 10 business days after the submission date of the amendment statement on February 5, 2026.

<Text omitted>

(After amendment)

<Text omitted>

On February 4, 2026, following the conclusion of discussions between the Offeror and the relevant authorities regarding the notification required under Article 27, Paragraph 1 of the Foreign Exchange and Foreign Trade Act, the Offeror, upon receiving instructions from the Ministry of Economy, Trade and Industry and the Ministry of Health, Labor and Welfare, resubmitted the notification to the Minister of Finance and the Minister in charge of the relevant business sector via the Bank of Japan on February 4, 2026, which was accepted on the same date. Consequently, the Offeror submitted an amendment to the Tender Offer Registration Statement and extended the Tender Offer Period to February 20, 2026, which is the date 10 business days after the submission date of the amendment statement on February 5, 2026.

Following that, the statutory waiting period was reduced, enabling the acquisition of common stock of the Target from February 13, 2026. Consequently, the Offeror submitted an amendment to the Tender Offer Registration Statement and extended the Tender Offer Period to 45 business days, ending on March 2, 2026, which is 10 business days after the submission date of the amendment statement on February 13, 2026.

<Text omitted>

[II] Amendment of the Public Notice Regarding Commencement of Tender Offer

II. DETAILS OF THE TENDER OFFER

C. Tender Offer Period

1. Tender Offer Period at the Time of Initial Notice

(Before amendment)

From December 18, 2025 (Thursday) to February 20, 2026 (Friday) (40 business days)

(After amendment)

From December 18, 2025 (Thursday) to March 2, 2026 (Monday) (45 business days)

H. Settlement Start Date

(Before amendment)

March 2, 2026 (Monday)

(After amendment)

March 9, 2026 (Monday)

M. Other Conditions and Methods of the Purchase

2. Conditions for Withdrawal of the Tender Offer, Details Thereof, and Method of Disclosure for Withdrawal

(Before amendment)

If any of the events specified in Article 14, Paragraph 1, Item 1 (i) to (nu) and (wa) to (ne), Item 3 (i) to (chi) and (nu), Item 4 and Paragraph 2, Items 3 to 6 of the Order occurs, the Tender Offer may be withdrawn.

Additionally, if (i) the body responsible for executing the business of the Target decides to distribute dividends, or decides to submit a proposal to pay the above dividend to the shareholders' meeting of the target company to distribute dividends (excluding cases where the amount of money or other property distributed to shareholders is expected to be less than 10% of the book value of net assets on the balance sheet as of the end of the most recent fiscal year of the Target (6,122.5 million yen (Note))), with the record date being prior to the start of settlement of the Tender Offer, or (ii) the body responsible for executing the business of the Target decides to acquire treasury shares (excluding cases where the amount of money or other property exchanged for the acquisition of shares is expected to be less than 10% of the book value of net assets on the balance sheet as of the end of the most recent fiscal year of the Target (6,122.5 million yen)), it may be considered as a “matter equivalent to those listed from (i) to (tsu)” as specified in Article 14, Paragraph 1, Item 1 (ne) of the Order, and the Tender Offer may be withdrawn. Furthermore, “facts equivalent to those listed from (i) to (ri)” as specified in Article 14, Paragraph 1, Item 3 (nu) of the Order refer to (i) cases where it is discovered that there are false statements regarding important matters or omissions of important matters that should be stated in statutory disclosure documents previously submitted by the Target, and the Offeror was unaware of such false statements, etc., and (ii) cases where facts listed from (i) to (to) of the same item occur in an important subsidiary of the Target.

Furthermore, as stated in “F. Permission, Etc. Concerning Acquisition of Share Certificates, Etc.,” “2. Governing Law” above, if, by the day before the expiration of the Tender Offer Period (including any extension), the Minister of Finance and the competent minister deem it necessary to review whether a notification under Article 27, Paragraph 1 of the Foreign Exchange and Foreign Trade Act constitutes an inward direct investment, etc., related to national security, etc., or deem it to constitute such an inward direct investment, etc., related to national security, etc., and if consequently the waiting period before the Offeror is allowed to acquire the Target Shares is extended, or if a

recommendation is made to change or cancel the details of such inward direct investment, etc., the Tender Offer may be withdrawn, etc., on the grounds that the “permission, etc.” under Article 14, Paragraph 1, Item 4 of the Order had not been obtained.

If a withdrawal is to be made, a public notice will be made electronically, and a notice will to that effect will be published in the Nihon Keizai Shimbun. However, if it is difficult to make a public notice by the last day of the Tender Offer Period, the announcement will be made by the method prescribed in Article 20 of the Cabinet Office Ordinance, followed by an immediate public notice.

(Note) Assuming there is no change in the total number of issued shares of the Target and the number of treasury shares, the dividend per share would be equivalent to 284 yen (specifically, the amount equivalent to 10% of the net assets of 61,225 million yen in the non-consolidated financial statements of the Target as of March 31, 2025, as stated in the Target’s 64th Fiscal Year Annual Securities Report, namely, 6,122.5 million yen, is divided by the Adjusted Total Number of Issued Shares of the Target (21,559,772 shares), and any fraction less than one yen is rounded up.).

(After amendment)

If any of the events specified in Article 14, Paragraph 1, Item 1 (i) to (nu) and (wa) to (ne), Item 3 (i) to (chi) and (nu) and Paragraph 2, Items 3 to 6 of the Order occurs, the Tender Offer may be withdrawn.

Additionally, if (i) the body responsible for executing the business of the Target decides to distribute dividends, or decides to submit a proposal to pay the above dividend to the shareholders' meeting of the target company to distribute dividends (excluding cases where the amount of money or other property distributed to shareholders is expected to be less than 10% of the book value of net assets on the balance sheet as of the end of the most recent fiscal year of the Target (6,122.5 million yen (Note))), with the record date being prior to the start of settlement of the Tender Offer, or (ii) the body responsible for executing the business of the Target decides to acquire treasury shares (excluding cases where the amount of money or other property exchanged for the acquisition of shares is expected to be less than 10% of the book value of net assets on the balance sheet as of the end of the most recent fiscal year of the Target (6,122.5 million yen)), it may be considered as a “matter equivalent to those listed from (i) to (tsu)” as specified in Article 14, Paragraph 1, Item 1 (ne) of the Order, and the Tender Offer may be withdrawn. Furthermore, “facts equivalent to those listed from (i) to (ri)” as specified in Article 14, Paragraph 1, Item 3 (nu) of the Order refer to (i) cases where it is discovered that there are false statements regarding important matters or omissions of important matters that should be stated in statutory disclosure documents previously submitted by the Target, and the Offeror was unaware of

such false statements, etc., and (ii) cases where facts listed from (i) to (to) of the same item occur in an important subsidiary of the Target.

If a withdrawal is to be made, a public notice will be made electronically, and a notice will to that effect will be published in the Nihon Keizai Shimbun. However, if it is difficult to make a public notice by the last day of the Tender Offer Period, the announcement will be made by the method prescribed in Article 20 of the Cabinet Office Ordinance, followed by an immediate public notice.

(Note) Assuming there is no change in the total number of issued shares of the Target and the number of treasury shares, the dividend per share would be equivalent to 284 yen (specifically, the amount equivalent to 10% of the net assets of 61,225 million yen in the non-consolidated financial statements of the Target as of March 31, 2025, as stated in the Target's 64th Fiscal Year Annual Securities Report, namely, 6,122.5 million yen, is divided by the Adjusted Total Number of Issued Shares of the Target (21,559,772 shares), and any fraction less than one yen is rounded up.).

[Restrictions on Solicitation]

This press release is a press release to announce the Tender Offer to the public and has not been prepared for the purpose of soliciting sales. When offering to sell, please make sure to read the Tender Offer Explanatory Statement regarding the Tender Offer and offer at your own discretion. This press release does not constitute or form part of any offer or solicitation to sell, or any solicitation of offers to purchase any securities, nor shall this press release (or any part thereof) or the fact of its distribution form the basis of any agreement relating to the Tender Offer, nor may it be relied upon in entering into any such agreement.

[Forward-Looking Statements]

This press release may contain expressions related to future outlooks, such as “expect,” “anticipate,” “intend,” “plan,” “believe,” and “assume,” concerning the future business on the part of the Offeror and other companies. These expressions are based on the Offeror’s current business forecast and may change due to future circumstances. The Offeror is not obligated to update these forward-looking statements to reflect actual performance or changes in various circumstances or conditions, and so forth.

[U.S. Regulations]

The Tender Offer will be conducted in accordance with the procedures and information disclosure standards prescribed by Japanese law, while these may differ from the procedures and information disclosure standards in the United States. In particular, the provisions of Article 13 (e) or Article 14 (d) of the U.S. Securities Exchange Act of 1934 (as amended; hereinafter the same) and the related rules stipulated thereunder do not apply to the Tender Offer, and the Tender Offer is not carried out in compliance with these procedures and standards. The financial information included in this press release and its reference documents are based on accounting principles in Japan, and therefore, is not in accordance with the U.S. accounting standards and may not be equivalent to, or comparable with, financial information prepared in accordance with the U.S. accounting standards. In addition, since the Offeror is a corporation incorporated outside the U.S. and all or some of its officers are not U.S. residents, it may be difficult to exercise rights or demands which would be claimed under the U.S. securities laws. It may not be able to bring legal proceedings against a non-U.S. entity or its officers in a court outside of the U.S. for violation of U.S. securities related laws. Furthermore, U.S. courts may not necessarily have jurisdiction over non-U.S. entities and their subsidiaries and affiliates.

Unless otherwise specified, all procedures relating to the Tender Offer are to be conducted entirely in Japanese. All or any part of the document related to the Tender Offer is prepared in the English language and if there is any inconsistency between the English-language documentation and the Japanese-language documentation, the Japanese-language documentation shall prevail.

This press release and its reference documents include “forward-looking statements” as defined in Section 27A of the U.S. Securities Act of 1933 (Securities Act of 1933; as amended) and Section 21E of the Securities Exchange Act (Securities Exchange Act of 1934). The results may significantly differ from those explicitly or implicitly indicated as “forward-looking statements” due to known or unknown risks, or uncertainties, or other causes. Neither the Offeror nor any of its affiliates can provide assurance that such results explicitly or implicitly indicated as “forward-looking statements” will be realized. The “forward-looking statements” in this press release and its reference documents were prepared based on the information held by the Offeror as of today, and unless required by laws and regulations or financial instruments exchange rules, the Offeror, the Target and its affiliates are not obliged to change and/or modify such statements in order to reflect any event or condition in the future.

The Offeror and its affiliates, and the financial advisors of the Offeror, EQT, and the Target; and

the tender offer agent (including their affiliates), may, within the ordinary course of their business and to the extent permitted under Japanese financial instruments and exchange regulations and other applicable laws, and in compliance with the requirements of Rule 14e-5(b) under the U.S. Securities Exchange Act of 1934, purchase or take actions to purchase Target Shares for their own account or for the account of their clients, either before the commencement of the Tender Offer or during the Tender Offer Period, outside of the Tender Offer. Such purchases may be conducted at market prices through market transactions or at prices determined through negotiations outside the market. If information regarding such purchases is disclosed in Japan, it will also be disclosed on the English-language website of the entity that conducted the purchase or its affiliates.

[Other Countries]

Certain countries or regions may impose legal restrictions on the announcement, publication, or distribution of this press release. In such cases, please be aware of and comply with those restrictions. This shall not constitute a solicitation of an offer to purchase or an offer to sell shares in connection with the Tender Offer, and shall be deemed to be merely the distribution of materials for information.